Tocilizumab and sarilumab reduced the risk of death in patients with COVID-19 severe illnesses

A recent REMAP CAP study found that Tocilizumab and sarilumab can reduce the mortality rate in patients with COVID-19 by 8.5 percent and shorten the recovery time of patients.
tocilizumab and sarilumab also reduced the amount of time seriously ill people spend in the ICU by about a week.
S. Health Minister Matt Hancock said: "This result is another milestone in moving away from the COVID-19 pandemic, which will play an important role in defeating COVID-19 when added to the vaccines and treatments already available."
REMAP CAP study involved about 800 severely ill patients from six countries, including the UK.
another study (RECOVERY trial) previously found that dexamisson reduced mortality in patients with COVID-19 by a third.
, according to the BBC, the cost of dexamisong is relatively low compared to Tocilizumab and sarilumab (about 5 pounds per course of treatment), while the cost of Tocilizumab and sarilumab is about 750-1000 pounds.
, lead researcher on the REMAP CAP study, commented: "Tocilizumab and sarilumab have great advantages in saving patients' lives."
。